HOME >> BIOLOGY >> NEWS
Images of 'tail' of protein needed for cell multiplication suggest anticancer drug targets

molecule called an "adenyl" group onto the end of NEDD8). Immediately after activating NEDD8, E1 forms a chemical bond with this protein. E1 then transfers NEDD8 to E2. Finally, E2 transfers NEDD8 to the E3 enzyme, which completes the workshop's job by binding NEDD8 to Cul1.

"This step-by-step process requires that all the molecules be brought together in a specific manner so the reactions can take place quickly," Schulman said. "That's where the E2 tail comes into play. The shape and location of E2's tail make it perfectly suited for drawing E1 close to NEDD8 so those two proteins can rapidly bind to each other and begin the process of assembling the on switch." The workshop's ability to quickly assemble the on switch is important because it reflects the need for cells to be able to react swiftly to a changing environment, according to Martine Roussel, Ph.D., member of St. Jude Genetics and Tumor Cell Biology and an author of the paper.

"Cells must be able to respond quickly to the changing demands and cues of their internal and external environments," Roussel said. "Often, the best way to respond rapidly is for the cell to modify a particular protein that already exists, rather than take the time to make a new one. Once modified, the existing protein becomes active and can quickly set off a specific cascade of biochemical reactions that performs a specific function in the cell."

The E1, E2 and E3 enzymes that make up the workshop that prepares NEDD8 to modify Cul1 are variations of a larger family of similar enzymes, according to the researchers. These other enzymes are part of the so-called ubiquitin pathway that puts molecular tags on proteins to signal that they should be destroyed. The ubiquitin pathway has dozens of different types of E2 enzymes, hundreds of different types of E3 enzymes and thousands of different targets. The NEDD8 workshop, however, has only one E2 and a few E3 enzymes, and NEDD8 itself has only a few target molecule
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
13-Sep-2004


Page: 1 2 3 4

Related biology news :

1. Images reveal how rotavirus - leading cause of diarrhea - enters cells
2. Images reveal how body regulates salt uptake in cells
3. Images of evolution
4. Images of enzyme suggest way to improve DNA sequencing
5. Laser Microscope At Cornell Images Serotonin In Live Cells
6. New molecular link key to cellular proteins involved in cancer progression, other diseases
7. Researchers identify protein promoting vascular tumor growth
8. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
9. Experimental drug shown to block mutant protein causing blood disease
10. Loss of the neuronal adhesion protein d-catenin leads to severe cognitive dysfunction
11. New dye directly reveals activated proteins in living cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
Cached News: